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Background: Most patients diagnosed with diabetes mellitus < 35 years will have type 1 diabetes (T1D). The increase in youth-
onset type 2 diabetes (T2D) parallels the obesity epidemic and in African subjects ketosis-prone type 2 diabetes (KPD) may occur 
in this age group.
Objectives, setting and subjects: To evaluate the clinical, biochemical and immunologic characteristics of patients diagnosed 
with diabetes < 35 years presenting to a tertiary diabetes clinic in Durban, South Africa over 13 years.
Design: A retrospective chart review of patients < 35 years diagnosed with diabetes was conducted. Data included clinical and 
laboratory variables, complications and follow-up status.
Results: The study included 517 patients of whom 445 (86.1%) were diagnosed with T1D, 27 (5.2%) with T2D, 27 with KPD (5.2%) 
and 18 (3.5%) with other forms of diabetes. Mean age of the total group was 28 ± 10 years. Subjects with T1D were younger at 
diagnosis with a lower BMI than both T2D and KPD. HbA1c was higher in subjects with T1D. Overall mortality was low (3.5%) and 
follow-up was poor in all groups.
Conclusion: The majority of young people with diabetes in KwaZulu-Natal, South Africa, have T1D, with small numbers of other 
types. Glucose control is poor with a high loss to follow-up.
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Introduction
The aetiologic type of diabetes mellitus occurring in young 
persons has for many years been regarded as predominantly 
type 1 diabetes (T1D) and in most parts of the world this is still 
the case.1,2 In addition, in many countries, the incidence of T1D is 
rising at a rate of approximately 3% per year.1 However, as the 
prevalence of obesity has rapidly increased in many communities, 
early onset type 2 diabetes (T2D) has emerged as an increasingly 
common diagnosis in young people.3,4 Furthermore, obesity may 
occur in patients with T1D, making the assignment of a specific 
aetiologic diagnosis in a young person more difficult.4
A recent systematic review of the global trends of T2D in youth 
found that there was substantial variation in both the incidence 
and prevalence, depending on the population and study 
methods.5 Although methodical dissimilarities have resulted in 
variable estimates, studies in the USA and Europe have shown a 
higher prevalence of young-onset T2D in ethnic minorities than 
in their white counterparts.5
The search for diabetes in youth (SEARCH) study, from the USA, is 
one of the largest studies to examine, through registries, the 
prevalence, incidence and clinical features of diabetes in young 
persons with diabetes. This study recruited patients under 20 years 
of age from five sites in the USA and enrolled incident cases in a 
prospective cohort study.6,7 Between 2001 and 2009, the 
prevalence was found to have increased for all types of diabetes: 
for type 1 diabetes (T1D) by 21.1% and for type 2 diabetes (T2D) 
by 30.5%.8 Of note was that these increases were higher in 
minority racial and ethnic groups than in non-Hispanic whites.8
Other countries in Europe, Canada, Australia and Israel have also 
developed registries for the study of children and adolescents 
with early onset T2D.9 From developing nations, India and 
Malaysia have commenced systematic data collection on 
diabetes in young people; these studies have, for the most part, 
shown that T1D is still the most common aetiologic type amongst 
youth in those countries, although a substantial number of 
young patients are diagnosed with T2D.9,10 From India, a multi-
centre registry of diabetes diagnosed under 25  years of age 
showed that 63.9% of the subjects had T1D and 25.3% had T2D. 9 
In Malaysia, the DiCARE registry showed that the majority (71.8%) 
of patients under 20 years of age had T1D, whereas 17.7% had 
T2D and 7.1% had other types of diabetes.10
There are very few studies examining the prevalence of diabetes 
in youth in Africa. Studies of diabetes in youth in sub-Saharan 
Africa (SSA) have been restricted to clinical studies on T1D. The 
four clinical studies (two in South Africa, and one each in Tanzania 
and Ethiopia) showed that the peak age of onset of T1D was later 
in African people than in European populations.11 Furthermore, 
the later age of onset of T1D in African subjects may have led to 
under-estimation of the prevalence of the disease in studies 
where lower age cut-off points were used.12
Ketosis-prone type 2 diabetes (KPD) is a sub-type of diabetes 
seen most frequently in persons of African origin.13 Although the 
mean age at diagnosis of KPD is 40 years, this condition may also 
affect young people.13 KPD is characterised by onset of 
ketoacidosis, male predominance, low prevalence of beta-cell 
autoantibodies and high rates of either remission or insulin-
independence after initial stabilisation.13
In view of the changes in the epidemiology and clinical 
presentation of diabetes in young persons in other parts of the 
world and the lack of data from South Africa, the present study 
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was undertaken to determine the specific types of diabetes 
affecting young people presenting to a tertiary referral hospital 
in Durban, KwaZulu-Natal and to describe the disease profile in 
terms of mode of presentation, beta-cell autoimmunity, beta-cell 
function and treatment requirements. It was hypothesised that 
diabetes in young people referred to this centre is not only T1D, 
but includes other aetiological types such as early onset T2D and 
KPD; furthermore, that T1D is not invariably associated with low 
body mass, but also occurs in obese individuals.
Subjects, materials and methods
This study was a retrospective chart review of patients attending 
the adult diabetes clinic at Inkosi Albert Luthuli Central Hospital 
(IALCH) in Durban, KwaZulu-Natal, over a 13-year period 
(February 2003–August 2016). IALCH is an 892-bed hospital that 
provides specialist and sub-specialist levels of health care. It is 
the tertiary referral hospital for the province of KwaZulu-Natal 
and parts of the Eastern Cape in South Africa. The study was 
approved by the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (reference number BE 548/16).
All patients who were younger than 35 years of age at the time of 
diabetes diagnosis were included in the study; patients who 
were diagnosed after the age of 35 years were excluded.
IALCH has a computerised patient record system allowing data 
storage and retrieval and data for the current study were 
extracted from this system. For each patient, information was 
recorded for clinical, laboratory and radiological data.
Demographic data included date of birth, current age, age at 
diabetes diagnosis, ethnic group and gender. Anthropometric 
measures included the last recorded weight, height, body mass 
index, waist and hip circumference. The mode of presentation of 
diabetes was recorded as asymptomatic, symptomatic or diabetic 
ketoacidosis (DKA). Hypertension was defined as the use of anti-
hypertensive treatment or if the last available blood pressure 
reading was ≥ 140/80 mmHg. Dyslipidaemia was defined as the 
use of a lipid-lowering agent or total serum cholesterol > 4.5 mmol/l, 
low-density lipoprotein (LDL) cholesterol  >  2.5  mmol/l or total 
triglycerides > 1.7 mmol/l on the last measurement.14
Each patient’s treatment requirements were documented. This 
included whether the patient was on oral anti-hyperglycaemic 
agents or insulin therapy or both. Details of oral treatment 
included the type of medication and dosage. Insulin therapy was 
recorded as type of insulin and doses used.
Data on diabetes complications included the presence of 
autonomic and peripheral neuropathy, based on information in 
the clinical record. Retinopathy was assessed by fundal 
photography and was documented as ‘yes’ if present at any point 
during the course of the disease. Microalbuminuria was present 
if a spot urine albumin-creatinine ratio exceeded 3.0 mg/mmol. 
Proteinuria was defined as dipstick positivity.
For laboratory data, the most recent glycated haemoglobin 
(HbA1c), serum fructosamine and lipids were recorded. The 
presence or absence of anti-glutamic acid decarboxylase (GAD) 
and anti-islet antigen 2 (IA2) antibodies was noted and fasting 
and glucagon-stimulated c-peptide levels, measured within 
12 months after diagnosis, were recorded. HbA1c was measured 
by high-performance liquid chromatography (Tosoh Bioscience 
LLC, King of Prussia, PA, USA) and fructosamine by calorimetric 
assay (Roche Modular; Roche Diagnostics, Basel, Switzerland). 
Serum lipids were measured by enzymatic reaction (Siemens 
Advia; Siemens Healthineers, Erlangen, Germany). Anti-GAD and 
anti-IA2 were measured by ELISA (Euroimmun, Lübeck, Germany) 
and c-peptide by chemiluminescent assay (Roche Electrosys).
The findings of ultrasound of the pancreas were recorded as well 
the most recent isotope glomerular filtration rate (iGFR), which 
was measured with the Multi-Channel Well Counter (Perkin 
Elmer 2470 Wizard 2 gamma counter, USA) after injection of 500 
μCi 99mTc-DTPA (diethylenetriamine penta acetate) and sampling 
at 2 and 3 hours post-injection.
Patients were categorised according to whether they were 
attenders, non-attenders (not seen in the last year), known to be 
deceased according to the records, or unknown status.
Definitions
Type 1 diabetes was defined if ≥ 1 of the following was present: 
presentation with DKA; positive anti-GAD or IA2 antibodies; 
fasting c-peptide (measured within the first year) < 0.75 ng/ml or 
glucagon-stimulated c-peptide < 1.8 ng/ml and absolute insulin 
dependence.15 Type 2 diabetes was defined as insidious 
presentation, absence of anti-GAD and anti-IA2 antibodies, 
insulin independence, clinical markers of insulin resistance and 
c-peptide levels above the T1D threshold.15 Ketosis-prone 
diabetes was defined in persons who presented with DKA or had 
an episode of DKA, absence of anti-GAD and anti-IA2 antibodies 
and initial insulin dependence with possible subsequent 
transition to oral therapy.13,16
Statistical analysis
Data were analysed with SPSS version 23 (SPSS Inc, Chicago, IL, 
USA). Data are presented as mean ± SD for continuous variables 
and as percentages for categorical variables. Pearson’s chi-square 
and Fisher’s exact test of association were used for categorical 
variables. Post hoc Bonferroni-corrected ANOVA or Kruskal–
Wallis tests were used to correct p-values for continuous 
variables. Student’s t-test was used for intergroup comparisons 
between different aetiological types as well as comparison of 
aetiological types between Asians. A p-value of  <  0.05 was 
considered statistically significant.
Results
The total study group included 517 individuals (males 220: 
females 297); of these, 86.1% (n = 445) were categorised as T1D 
and 5.2% (n = 27) as T2D and KPD, respectively. The remaining 
3.5% (n = 18) had various types of diabetes. The subsequent 
results refer to subjects classified as T1D, T2D and KPD. The 18 
subjects with miscellaneous diagnoses were excluded from 
further analysis.
Demography
The patient characteristics are given in Table 1. The majority, in all 
categories of diabetes, were African (black) who comprised 
61.6% (n = 274) of patients with T1D, 55.6% (n = 15) of T2D and all 
(100%) (n = 27) KPD patients. Asian patients were more often 
diagnosed with T2D (40.7%; n = 11) than T1D (25.8%; n = 115) 
(p = 0.047).
Gender distribution was similar, both for the total group as well 
as for each diabetes type. Mean age at diagnosis was significantly 
lower in T1D (15 ± 7 years) and T2D (17 ± 6 years) than in KPD 
(24 ± 7 years) (p = 0.002). Patients with T1D had a longer duration 
of disease (13  ±  9  years) than the other two groups (T2D 
9 ± 7 years; KPD 5 ± 3 years) (p = 0.05).
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Mode of presentation
There was a significant overall difference between the groups for 
mode of presentation (p < 0.001). Almost half the group with T1D 
(46.5%; n = 207) presented with ketoacidosis and the majority of 
the remainder (45.4%; n = 202) presented with symptomatic 
hyperglycaemia. All but one of the KPD patients presented with 
DKA (96.3%; n = 26) and the single patient that did not present 
with DKA developed this complication shortly after the diagnosis 
of diabetes. The majority (85.2%; n = 23) of patients with T2D 
presented with symptomatic hyperglycaemia without 
ketoacidosis (see Table 1).
Clinical characteristics
Subjects with T1D had significantly lower BMI and smaller waist 
circumference than the other two groups (BMI (kg/m2) T1D 
24.4 ± 5.1; T2D 28.4 ± 4.5, p < 0.001; KPD 32.4 ± 6.8, p < 0.001) 
(waist circumference (cm) T1D 80.4 ± 11.1; T2D 89.4 ± 10.6, p < 
0.001; KPD 97.2  ±  12.8, p < 0.001). There was no difference 
between the groups for blood pressure, prevalence of 
hypertension, dyslipidaemia or complications (Table 2).
Autoimmunity and beta-cell function
Autoantibodies were available for 364 of T1D, 24 of T2D and 25 
KPD patients. Anti-GAD/IA2 antibodies were detected in a 
significantly higher number of patients with T1D (72.5%; n = 264) 
than those diagnosed as T2D (0%; n = 0) (p < 0.001) or KPD (8%; n 
= 2) (p < 0.001) (Table 3).
Fasting and glucagon-stimulated c-peptide levels were 
significantly lower in those with T1D (fasting 0.36  ±  0.46; 6 
minute 0.49  ±  0.64  ng/ml), compared with T2D (fasting 
1.84 ± 1.31; 6 minute 3.66 ± 2.97 ng/ml, p < 0.001 for both 0 and 
6 minutes) and KPD (fasting 1.43 ± 0.89; 6 minute 2.99 ± 1.91 ng/
ml, p < 0.001 for both 0 and 6 minutes) (see Table 3).
Glycaemic control and treatment
Glycaemic control was suboptimal in all groups, but significantly 
worse in T1D. Mean HbA1c in subjects with T1D was 11.1 ± 3.0%, 
(98  ±  33  mmol/mol), compared with T2D (9.4  ±  3.1%, 
80 ± 34 mmol/mol, p = 0.017) and KPD (8.6 ± 3.3%, 71 ± 36 mmol/
mol, p < 0.001) (Table 4).
Albuminuria, GFR and ultrasound pancreas
There was no difference observed between the three groups for 
the categories of urine albumin excretion, isotope GFR and 
ultrasound characteristics of the pancreas.
Table 1: Characteristics of the total study group (n = 499) according to 
diabetes type
Data shown as % (n) or mean ± SD.
T1D: type 1 diabetes; T2D: type 2 diabetes; KPD: ketosis-prone diabetes.
P-values are for comparisons between the three groups by ANOVA 
for continuous variables and Pearson’s chi-square test for categorical 
variables.
*vs. T1D; #vs. KPD, significant difference for inter-group comparison 
using Bonferroni adjusted t-tests.
Factor All T1D T2D KPD p-value




 African 63.3 (316) 61.6 (274) 55.6 (15) 100 (27)
 Indian 25.3 (126) 25.84 (115) 40.7 (11) 0
 White 7.8 (39) 8.5 (38) 3.7 (1) 0
 Mixed 
race
3.6 (18) 4 (18) 0 (0) 0
Gender: 0.354 
 Male 42.5 (212) 43.6 (194) 33.3 (9) 33.3 (9)
 Female 57.5 (287) 56.4 (251) 66.7 (18) 66.7 (18)
Age (yrs) 28 ± 10 28 ± 11 26 ± 10 30 ± 6 0.512 
Age at diag-
nosis (yrs)








3.4 (17) 2.7(12) 14.8 (4) 3.7 (1)
 Sympto-
matic
45.1 (225) 45.4 (202) 85.2 (23) 0 (0)
 DKA 46.7 (233) 46.5 (207) 0 (0) 96.3 (26)
 Unknown 4.8 (24) 0 0 0
Table 2: Clinical features based on aetiological type of diabetes 
(n = 499)
Data shown as % (n) or mean ± SD.
T1D: type 1 diabetes; T2D: type 2 diabetes; KPD: ketosis-prone diabetes.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure.
P-values are for comparisons between the three groups by ANOVA 
for continuous variables and Pearson’s chi-square test for categorical 
variables.
*vs. T1D; #vs. KPD, significant difference for inter-group comparison 
using Bonferroni adjusted t-tests.
Factor T1D T2D KPD p-value
n = 445 n = 27 n = 27
Height (m) 1.6 ± 0.10 1.61 ± 0.1 1.6 ± 0.1 0.945
Weight (kg) 62.9 ± 14.6 73.5 ± 12.0*# 83.3 ± 20.5* < 0.001
BMI (kg/m2) 24.4 ± 5.1 28.4 ± 4.5*# 32.4 ± 6.8* < 0.001
Waist (cm) 80.4 ± 11.1 89.4 ± 10.6*# 97.2 ± 12.8* < 0.001
SBP (mmHg) 126 ± 15 131 ± 14 129 ± 14 0.101
DBP (mmHg) 74 ± 11 75 ± 12 76 ± 13 0.697
Hypertension 22.5 (100) 33.3 (9) 17.9 (5) 0.367
Dyslipidaemia 64.7 (288) 51.9 (14) 66.7 (18) 0.722
Neuropathy 29.5 (131) 25.9 (7) 25.9 (7) 0.991
Retinopathy 21.1 (91) 11.1 (3) 3.7 (1) 0.503
Table 3: Antibodies and c-peptide levels according to diabetes 
aetiology
Data shown as % (n) or mean ± SD.
T1D: type 1 diabetes; T2D: type 2 diabetes; KPD: ketosis-prone diabetes.
P-values are for comparisons between the three groups by ANOVA 
for continuous variables and Pearson’s chi-square test for categorical 
variables.
*vs. T1D; #vs. KPD, significant difference using Bonferroni adjusted 
t-tests.
§Anti-GAD/IA2 available for 364 T1D, 24 T2D and 25 KPD patients.
Factor T1D T2D KPD p-value
n = 445 n = 27 n = 27
Anti-GAD/IA2 
positive§
72.5 (264) 0 (0) * 8 (2) * < 0.001
c-peptide (ng/ml)
 0 minutes 0.36 ± 0.46 1.84 ± 1.31* 1.43 ± 0.89* < 0.001
 6 minutes 0.49 ± 0.64 3.66 ± 2.97* 2.99 ± 1.91* < 0.001
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 Male 42.5 (212) 43.6 (194) 33.3 (9) 33.3 (9)
 Female 57.5 (287) 56.4 (251) 66.7 (18) 66.7 (18)
Age (yrs) 28 ± 10 28 ± 11 26 ± 10 30 ± 6 0.512 
Age at diag-
nosis (yrs)








3.4 (17) 2.7(12) 14.8 (4) 3.7 (1)
 Sympto-
matic
45.1 (225) 45.4 (202) 85.2 (23) 0 (0)
 DKA 46.7 (233) 46.5 (207) 0 (0) 96.3 (26)
 Unknown 4.8 (24) 0 0 0
Table 2: Clinical features based on aetiological type of diabetes 
(n = 499)
Data shown as % (n) or mean ± SD.
T1D: type 1 diabetes; T2D: type 2 diabetes; KPD: ketosis-prone diabetes.
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure.
P-values are for comparisons between the three groups by ANOVA 
for continuous variables and Pearson’s chi-square test for categorical 
variables.
*vs. T1D; #vs. KPD, significant difference for inter-group comparison 
using Bonferroni adjusted t-tests.
Factor T1D T2D KPD p-value
n = 445 n = 27 n = 27
Height (m) 1.6 ± 0.10 1.61 ± 0.1 1.6 ± 0.1 0.945
Weight (kg) 62.9 ± 14.6 73.5 ± 12.0*# 83.3 ± 20.5* < 0.001
BMI (kg/m2) 24.4 ± 5.1 28.4 ± 4.5*# 32.4 ± 6.8* < 0.001
Waist (cm) 80.4 ± 11.1 89.4 ± 10.6*# 97.2 ± 12.8* < 0.001
SBP (mmHg) 126 ± 15 131 ± 14 129 ± 14 0.101
DBP (mmHg) 74 ± 11 75 ± 12 76 ± 13 0.697
Hypertension 22.5 (100) 33.3 (9) 17.9 (5) 0.367
Dyslipidaemia 64.7 (288) 51.9 (14) 66.7 (18) 0.722
Neuropathy 29.5 (131) 25.9 (7) 25.9 (7) 0.991
Retinopathy 21.1 (91) 11.1 (3) 3.7 (1) 0.503
Table 3: Antibodies and c-peptide levels according to diabetes 
aetiology
Data shown as % (n) or mean ± SD.
T1D: type 1 diabetes; T2D: type 2 diabetes; KPD: ketosis-prone diabetes.
P-values are for comparisons between the three groups by ANOVA 
for continuous variables and Pearson’s chi-square test for categorical 
variables.
*vs. T1D; #vs. KPD, significant difference using Bonferroni adjusted 
t-tests.
§Anti-GAD/IA2 available for 364 T1D, 24 T2D and 25 KPD patients.
Factor T1D T2D KPD p-value
n = 445 n = 27 n = 27
Anti-GAD/IA2 
positive§
72.5 (264) 0 (0) * 8 (2) * < 0.001
c-peptide (ng/ml)
 0 minutes 0.36 ± 0.46 1.84 ± 1.31* 1.43 ± 0.89* < 0.001
 6 minutes 0.49 ± 0.64 3.66 ± 2.97* 2.99 ± 1.91* < 0.001
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Discussion
This study showed that over a 13-year period, the majority (86.1%) 
of subjects diagnosed with diabetes under the age of 35 years, 
presenting to a tertiary diabetes clinic in South Africa, were 
classified as T1D, with smaller proportions designated as T2D 
(5.2%) and KPD (5.2%). When compared with T2D and KPD, 
patients with T1D were leaner, had a higher prevalence of anti-
GAD/IA2 antibodies, lower c-peptide levels and worse glycaemic 
control. All diagnosed with KPD were African patients; KPD 
patients were characterised by obesity and older age at diagnosis.
The prevalence of the various aetiological types of diabetes 
found in this study is similar to those reported from India and 
Malaysia.9,10 Both the Indian and Malaysian registries showed 
that most young patients, diagnosed under 25 and 20 years of 
age respectively, had T1D (63.9% and 71.8%). The SEARCH study 
in the USA showed a higher prevalence of T1D (1.94/1000) than 
T2D (0.48/1000) in subjects diagnosed at age < 20 years; but the 
SEARCH study also showed that the incidence of both T1D and 
T2D was increasing.7,8 In Ohio, USA, a study in the greater 
Cincinnati region showed an increase in incidence in both T1D 
and T2D between 1982 and 1994; however, the increase in the 
number of T2D patients outnumbered T1D.17 Studies in young 
people in Auckland, New Zealand (NZ) and Western Australia 
(WA) also showed a sharp rise in incidence of T2D.18,19
The finding that only 5.2% had T2D in this study is lower than that 
reported from India (25.8%) and Malaysia (17.7%).9,10 By contrast, 
the prevalence of T2D in youth has been reported to be higher 
than T1D in a study from a tertiary diabetes centre in India (48%) 
and in Maoris in New Zealand (55%).20,21 A possible reason for the 
lower prevalence of T2D in the current study is the presence of 
undiagnosed patients in the community, as screening for diabetes 
would usually only occur with the onset of symptoms. It is also 
possible that some young patients are treated in peripheral 
clinics and not referred to the tertiary centre. The patient profile 
in the present study also differed from the Indian and Malaysian 
studies in that most of the subjects were African and early onset 
T2D appears to be less frequent in patients of African origin than 
other ethnic groups.11,22,23 Of note, a higher proportion of Asian 
subjects in the current study were diagnosed with T2D than T1D 
(T1D 25.8% vs. T2D 40.7%). This may reflect variances in ethnic 
susceptibility to different types of diabetes. Furthermore, direct 
comparison between the present study and the SEARCH, Indian 
and Malaysian studies is influenced by the variable age cut-off 
points used in the various studies.7–10,20 The age cut-off point 
chosen in the current study was < 35 years and this was based on 
earlier observations that later age of onset of diabetes is reported 
in African communities (22–29 years) compared with European 
communities.4,11,22,24–26 Also, African patients had a bimodal peak 
of age of onset, with the first peak between 14 and 17 years and 
the second between 30 and 31 years.26
In the current study, all 27 KPD patients were African, older at 
diagnosis and heavier than subjects with T1D and T2D. The high 
mean BMI in the KPD group is compatible with other studies, 
which report BMI in subjects with KPD to range between 28 and 
37 kg/m².13 Only two (8%) patients with KPD were anti-GAD/IA2 
positive and both were treated with metformin and insulin. This 
is in line with previous reports that the presence of beta cell 
auto-antibodies does not exclude KPD; up to 18% of patients 
with KPD may be antibody positive and this finding may be 
useful in predicting insulin requirements.13
Treatment
Insulin doses in subjects with T1D (1.19  ±  0.5 units/kg) were 
similar to those with T2D (1.15 ± 0.67 units/kg) but significantly 
higher than patients with patients with KPD (0.89 ± 0.8 units/kg, 
p = 0.038). In patients with KPD, at last follow-up, most (48.2%; n 
= 13) of the group were being treated with a combination of oral 
anti-hyperglycaemic therapy and insulin; equal numbers of the 
remainder were either on oral therapy alone (25.9%; n = 7), or 
insulin alone (25.9%; n = 7).
T1D sub-groups
Patients with T1D with positive anti-GAD or IA2 antibodies 
(72.5%, n = 264) had a similar duration of disease (11  ±  8 vs. 
13 ± 10 years, p = 0.05), lower prevalence of microalbuminuria 
(68.6 vs. 84%, p = 0.004) and were treated with lower doses of 
insulin (1.1 ± 0.5 vs. 1.25 ± 0.5 units/kg, p = 0.047) than those who 
were antibody negative.
Follow-up status
No difference was noted between the groups in terms of non-
attender rates, although almost half the patients in every 
category had defaulted on follow-up (T1D 237 (53.3%); T2D 13 
(48.2%); KPD 11 (40.7%)). There were 16 known deaths (3.6%) in 
the T1D group with only one (3.7%) in the T2D group and none in 
the KPD group. The cause of death was unknown in the majority 
of cases.
Table 4: Measures of glycaemic control, renal function and pancreatic 
ultrasound according to diabetes type
Data shown as % (n) or mean ± SD.
T1D: type 1 diabetes; T2D: type 2 diabetes; KPD: ketosis-prone diabetes.
iGFR: isotope glomerular filtration rate.
P-values are for comparisons between the three groups by ANOVA.
*vs. T1D; #vs. KPD, significant difference using t-test.
Factor T1D T2D KPD p-value
n = 445 n = 27 n = 27
HbA1c (%) 11.1 ± 3.0 9.42 ± 3.1* 8.6 ± 3.3* < 0.001
HbA1c (mmol/
mol)








 Normal 57.3 (254) 51.9 (14) 74.1 (20)
 Microalbu-
minuria
 25.5 (113) 25.9 (7) 14.8 (4)
 Macroalbu-
minuria
 17.2 (76) 22.2 (6) 11.1 (3)
iGFR (ml/min/
m2)




 Normal 62.9 (280) 85.2 (23) 85.2 (23)
 Calcific 0.9 (4) 0 (0) 0 (0)
 UTV 3.1 (14) 3.7 (1) 3.7 (1)




1.19 ± 0.5 1.15 ± 0.67 0.89 ± 0.8* 0.038
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high percentage of unknown outcomes in both the T1D and T2D 
groups.10
This study had several limitations. The retrospective nature of the 
study precludes the evaluation of incidence trends in each 
aetiologic group. Other limitations include the small numbers of 
patients with T2D and KPD, which limits the accuracy of inter-
group comparisons. Furthermore, the high non-attender status 
prevents assessment of patient outcome and the paucity of data 
from other countries in Africa regarding young onset T2D 
prevents comparison within the continent.12 Furthermore, T2D 
may be asymptomatic for a number of years prior to the diagnosis 
and the number of patients with T2D may be higher than 
currently detected.21
Conclusion
The majority of young patients with diabetes in KZN have T1D 
and most have positive beta-cell autoantibodies. The phenotype 
of T1D is not characterised by overweight or obesity, in contrast 
to those with T2D and KPD. Overall glycaemic control is 
suboptimal and non-attender status is high amongst all the 
groups. Future prospective population-based studies are needed 
in order to assess the incidence and prevalence of the various 
types of diabetes in young people in South Africa.
Disclosure statement – No potential conflict of interest was 
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obesity were not shown to be a phenotypic feature of T1D in the 
population in this study. By contrast, 44.4% (n = 12) patients with 
T2D in this study were overweight and 29.6% (n = 8) patients 
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patient with T1D and three with T2D were lost to follow-up and 
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However, as in this study, the numbers from the Malaysian 
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high percentage of unknown outcomes in both the T1D and T2D 
groups.10
This study had several limitations. The retrospective nature of the 
study precludes the evaluation of incidence trends in each 
aetiologic group. Other limitations include the small numbers of 
patients with T2D and KPD, which limits the accuracy of inter-
group comparisons. Furthermore, the high non-attender status 
prevents assessment of patient outcome and the paucity of data 
from other countries in Africa regarding young onset T2D 
prevents comparison within the continent.12 Furthermore, T2D 
may be asymptomatic for a number of years prior to the diagnosis 
and the number of patients with T2D may be higher than 
currently detected.21
Conclusion
The majority of young patients with diabetes in KZN have T1D 
and most have positive beta-cell autoantibodies. The phenotype 
of T1D is not characterised by overweight or obesity, in contrast 
to those with T2D and KPD. Overall glycaemic control is 
suboptimal and non-attender status is high amongst all the 
groups. Future prospective population-based studies are needed 
in order to assess the incidence and prevalence of the various 
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